- Home
- NUVL vs ALK Comparison
NUVL vs ALK Comparison
Compare NUVL & ALK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NUVL
- ALK
- Stock Information
- Founded
- NUVL 2017
- ALK 1932
- Country
- NUVL United States
- ALK United States
- Employees
- NUVL N/A
- ALK N/A
- Industry
- NUVL Biotechnology: Pharmaceutical Preparations
- ALK Air Freight/Delivery Services
- Sector
- NUVL Health Care
- ALK Consumer Discretionary
- Exchange
- NUVL Nasdaq
- ALK Nasdaq
- Market Cap
- NUVL 7.1B
- ALK 6.6B
- IPO Year
- NUVL 2021
- ALK N/A
- Fundamental
- Price
- NUVL $109.19
- ALK $37.89
- Analyst Decision
- NUVL Strong Buy
- ALK Strong Buy
- Analyst Count
- NUVL 13
- ALK 12
- Target Price
- NUVL $133.85
- ALK $72.17
- AVG Volume (30 Days)
- NUVL 734.4K
- ALK 4.0M
- Earning Date
- NUVL 10-30-2025
- ALK 10-23-2025
- Dividend Yield
- NUVL N/A
- ALK N/A
- EPS Growth
- NUVL N/A
- ALK N/A
- EPS
- NUVL N/A
- ALK 1.23
- Revenue
- NUVL N/A
- ALK $14,141,000,000.00
- Revenue This Year
- NUVL N/A
- ALK $22.78
- Revenue Next Year
- NUVL N/A
- ALK $7.24
- P/E Ratio
- NUVL N/A
- ALK $30.77
- Revenue Growth
- NUVL N/A
- ALK 31.50
- 52 Week Low
- NUVL $55.54
- ALK $37.63
- 52 Week High
- NUVL $112.88
- ALK $78.08
- Technical
- Relative Strength Index (RSI)
- NUVL 66.08
- ALK 29.04
- Support Level
- NUVL $93.05
- ALK $41.45
- Resistance Level
- NUVL $112.53
- ALK $39.86
- Average True Range (ATR)
- NUVL 5.84
- ALK 1.72
- MACD
- NUVL 1.06
- ALK -0.09
- Stochastic Oscillator
- NUVL 84.34
- ALK 1.59
About NUVL Nuvalent Inc.
Nuvalent Inc is a clinical-stage biopharmaceutical company focused on creating precisely targeted therapies for patients with cancer. All of the Company's operations are in the United States. The company is engaged in developing small molecules that are designed to overcome the limitations of existing therapies for clinically validated kinase targets. The product candidates of the company include NVL-520, which is being developed for patients with ROS1-positive non-small cell lung cancer (NSCLC), NVL-655, which is being developed for patients with anaplastic lymphoma kinase (ALK)-positive NSCLC, NVL-330, is a brain-penetrant human epidermal growth factor receptor 2 (HER2)-selective inhibitor designed to address the combined medical need of treating tumors driven by HER2ex20.
About ALK Alaska Air Group Inc.
Alaska Air Group Inc operates two airlines, Alaska and Horizon in three operating segments. The Alaska Airlines segment includes scheduled air transportation on Alaska's Boeing and Airbus jet aircraft for passengers and cargo throughout the U.S., and in parts of Mexico, and Costa Rica. The Regional segment includes Horizon's and other third-party carriers' scheduled air transportation for passengers across a shorter distance network within the U.S. and Canada under capacity purchase agreements (CPA). The Hawaiian Airlines segment includes scheduled air transportation on Hawaiian's Boeing and Airbus aircraft for passengers and cargo. It earns revenues from Passenger tickets, including ticket breakage and net of taxes and fees, Passenger ancillary and Mileage Plan passenger revenue.